MedTrace Logo

Patients' Preferences for Adjuvant Endocrine Therapy in Early Breast Cancer

NCT03939156 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 450

Last updated 2023-06-28

No results posted yet for this study

Summary

Preference studies reveal how individuals trade-off the potential benefits, harms and inconveniences of a treatment by determining the minimum benefits they judge sufficient to make the treatment worthwhile.

They are especially relevant to adjuvant therapies where individuals must weigh up modest survival benefits only realized in time by no recurrence of their cancer with side effects predominantly experienced whilst on the treatment.

Previously it was reported, for example, that over 50% of women who had adjuvant chemotherapy for early breast cancer judged a 1% improvement in 5 year survival rates sufficient to make it worthwhile.

Larger survival benefits were required for longer duration adjuvant hormonal therapy where over 50% of women required at least 5% improvement in 5 year survival rates to make it worthwhile.

Conditions

Interventions

OTHER

Completion of questionnaires

Completion of questionnaires at the time of study entry

Sponsors & Collaborators

  • European Institute of Oncology

    lead OTHER

Principal Investigators

  • Emilia Montagna, MD · European Institute of Oncology

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-06-05
Primary Completion
2023-12-31
Completion
2023-12-31

Countries

  • Italy

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03939156 on ClinicalTrials.gov